Typical splicing of VEGF results in an anti-angiogenic splice variant VEGF165b, which is widely expressed in normal cells and tissues, but is down-regulated in prostate cancer [61] and potentially serves as an anti-angiogenic, anticancer therapeutic via either controlling VEGF splicing or targeted delivery [62]. Here, VEGFA is linked to prostate cancer.